Has Tung Wynn received payments from drug or device companies?

Yes. Drug and device makers reported $2,897 in general payments to Tung Wynn across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tung Wynn did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tung Wynn come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tung Wynn

Pediatric Hematology-Oncology · Gainesville, FLNPI 1295730737

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,000 of the $2,897 with a category attached, or 69.0%. Sanofi accounts for 70.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,155 and has fallen 99.3% since, to $14 in 2025.

$2,897in general payments, 2019–2025

Across 21 payments — averaging $137.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$2K
Bayer$223
Octapharma USA, Inc.$208
Regeneron$155
Takeda Pharmaceuticals U.S.A., Inc.$100
Kedrion Biopharma, Inc.$53
plus $115 from 3 others

$1,028,349in research payments, 2019–2025

Across 366 payments — averaging $2809.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$325K
Sanofi$259K
Sanofi US Services Inc.$188K
Bioverativ Therapeutics Inc.$68K
AMAG Pharmaceuticals, Inc.$58K
Sobi, Inc$34K
plus $96K from 8 others

What the payments were for

Consulting fees$1244%
Speaking & faculty fees$2,00069%
Food & beverage$73925%
Education$341%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	7	$2,042
Bayer	2	$223
Octapharma USA, Inc.	3	$208
Regeneron	1	$155
Takeda Pharmaceuticals U.S.A., Inc.	1	$100
Kedrion Biopharma, Inc.	1	$53
Shire North American Group Inc	1	$43
CSL Behring	1	$38
Pfizer	4	$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Jivi$223
Kovaltry$223
Kogenate FS$108
WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$102
VONVENDI$100

How this compares

$2,897 in reported general payments places this provider in the 70th percentile of 132 pediatric hematology-oncology providers in Florida.

See all pediatric hematology-oncology providers in Florida →

Other pediatric hematology-oncology in Gainesville

Lucien BlackGainesville$12K
Matthew CascioGainesville$8K
Jordan MilnerGainesville$3K
Sridharan GururanganGainesville$2K
Guillermo DeanguloMiami$929K
Shveta GuptaOrlando$714K
Joanna DavisMiami$411K
Fernando Corrales-MedinaMiami$335K
Erin CockrellTampa$260K
Jaime Libes-BanderOrlando$133K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →